Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-101 and/or HT-102 in Chronic Hepatitis B
NCT07183306Phase 2Active, not recruiting
- Sponsor
- Hepatera
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of HT-101 and HT-102 in Chronic Hepatitis B (CHB) (6 cohorts), sponsored by Hepatera. Primary endpoints: Clinically significant abnormalities at 60 weeks and Incidence of adverse events (AEs) and serious adverse events (SAEs) at 60 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
HT-101HT-102
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07183306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183306.